

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Virbagen Omega 5 MU lyophilisate and solvent for suspension for injection for dogs and cats  
Virbagen Omega 10 MU lyophilisate and solvent for suspension for injection for dogs and cats

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1 ml contains:

### Active substance:

Lyophilisate:

5 MU presentation:

Recombinant Omega interferon of feline origin                      5 MU\*

10 MU presentation:

Recombinant Omega interferon of feline origin                      10 MU\*

\*MU: Million Units

### Excipients:

<b>Qualitative composition of excipients and other constituents</b>
<b>Lyophilisate:</b>
Sodium hydroxide 0.2 M
Sodium chloride
D-Sorbitol
Purified gelatin of porcine origin
<b>Solvent:</b>
Sodium chloride
Water for injections

Lyophilisate: white colour.

Solvent: colourless liquid.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Dogs and cats.

### 3.2 Indications for use for each target species

Dogs:

Reduction of mortality and clinical signs of parvovirus (enteric form) in dogs from one month of age.

Cats:

Treatment of cats infected with FeLV (Feline Leukemia Virus) and/or FIV (Feline Immunodeficiency Virus), in non-terminal clinical stages, from the age of 9 weeks. In a field study conducted, it was observed that there was:

- a reduction of clinical signs during the symptomatic phase (4 months)
- a reduction of mortality:
  - in anaemic cats, mortality rate of about 60 % at 4, 6, 9 and 12 months was reduced by approximately 30 % following treatment with interferon.
  - in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20 % following treatment with interferon. In cats infected by FIV, mortality was low (5 %) and was not influenced by the treatment.

### **3.3 Contraindications**

Dogs: Vaccination during and after Virbagen Omega treatment is contraindicated, until the dog appears to have recovered.

Cats: as vaccination is contraindicated in the symptomatic phase of FeLV/FIV infections, the effect of Virbagen Omega on cat vaccination has not been evaluated.

### **3.4 Special warnings**

No information on the induction of long-term adverse reactions is available in dog and cat, especially for autoimmune disorders. Such side effects have been described after multiple and long-term administration of type I interferon in man. The possibility of occurrence of autoimmune disorders in treated animals cannot therefore be ruled out and has to be balanced with the risk associated with FeLV/FIV infections.

Efficacy of the product on cats with a tumorous form of the infection by FeLV, or cats infected by FeLV or coinfecting by FIV in terminal stages was not tested.

In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.

### **3.5 Special precautions for use**

Special precautions for safe use in the target species:

Dogs and cats: it was shown that strict compliance with the recommended posology is compulsory to achieve clinical benefit.

Cats: In case of repeated treatments of chronic diseases associated with hepatic, cardiac and renal failure, the corresponding disease has to be monitored prior to administration of Virbagen Omega.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

### **3.6 Adverse events**

Dogs:

Very common (>1 animal / 10 animals treated):	Decreased white blood cells <sup>1</sup> , Decreased platelet count <sup>1</sup> , Decreased red blood cell count <sup>1</sup> , Elevated alanine aminotransferase (ALT) <sup>1</sup>
Common (1 to 10 animals / 100 animals treated):	Hyperthermia <sup>2,3</sup> Lethargy <sup>2</sup>

<sup>1</sup>Slight, Return to normal in the week following the last injection.

<sup>2</sup>Slight and Transient.

<sup>3</sup>3-6 hours after injection.

Cats:

Very common (>1 animal / 10 animals treated):	Decreased white blood cells <sup>1</sup> , Decreased platelet count <sup>1</sup> , Decreased red blood cell count <sup>1</sup> , Elevated alanine aminotransferase (ALT) <sup>1</sup>
Common (1 to 10 animals / 100 animals treated):	Hyperthermia <sup>2,3</sup> Lethargy <sup>2</sup> Digestive tract disorders (e.g. Diarrhoea, Vomiting) <sup>2</sup>

<sup>1</sup>Slight, Return to normal in the week following the last injection.

<sup>2</sup>Slight and Transient.

<sup>3</sup>3-6 hours after injection.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

### 3.8 Interaction with other medicinal products and other forms of interaction

The use of supplementary supportive treatments improves prognosis. No interaction has been observed during the treatment with Virbagen Omega together with antibiotics, solution for rehydration, vitamins and non steroidal anti-inflammatory agents. However, as specific information on possible interactions of interferon with other products are missing, supplementary supportive treatments should be used cautiously and after a thorough risk/benefit analysis.

No information is available on the safety and efficacy of this product when used with any other vaccine. For dogs, it is recommended that no vaccines should be administered until the animal appears to have recovered. Cat vaccination during and after Virbagen Omega treatment is contraindicated as both FeLV and FIV infections are known to be immunosuppressive.

### 3.9 Administration routes and dosage

Dogs: Intravenous use

Cats: Subcutaneous use

The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain, depending on the presentation, a limpid and colourless suspension containing 5 MU or 10 MU of recombinant interferon.

Dogs:

The reconstituted product should be injected intravenously once daily for 3 consecutive days. The dose is 2.5 MU/kg bodyweight.

#### Cats:

The reconstituted veterinary medicinal product should be injected subcutaneously once daily for 5 consecutive days. The dose is 1 MU/kg bodyweight. Three separate 5-day treatments must be performed at day 0, day 14 and day 60.

The veterinary medicinal product should be used with the accompanying solvent only.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

After a tenfold overdose in both dog and cat the following clinical signs have been observed:

- mild lethargy and drowsiness.
- slight increase of body temperature.
- slight increase of respiratory rate.
- slight sinus tachycardia.

These clinical signs disappear within 7 days without any particular treatment.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

### **3.12 Withdrawal periods**

Not applicable.

## **4. IMMUNOLOGICAL INFORMATION**

### **4.1 ATCvet code: QL03AB**

Omega interferon of feline origin, produced by genetic engineering, is a type I interferon closely related to alpha interferon.

The exact mechanism of action of interferon omega is not perfectly known, but may involve enhancement of the non-specific defence of the body, in particular in the dog against canine parvovirus and in the cat against feline retrovirus (FeLV, FIV). Interferon does not act directly and specifically on the pathogenic virus, but exerts its effect by inhibition of the internal synthesis mechanisms of the infected cells.

After injection it is quickly bound to specific receptors of a large variety of cells. It is mainly in cells infected by virus that the mechanism of replication is stopped both by destruction of mRNA and by inactivation of translation proteins (2'5' oligo-adenylate synthetase activation).

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product, except solvent supplied for use with the product.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after reconstitution according to directions: use immediately.

### **5.3 Special precautions for storage**

Store and transport refrigerated (2 °C – 8°C).  
Do not freeze.  
Store in the original package.

### **5.4 Nature and composition of immediate packaging**

#### Lyophilisate:

Type I glass vial closed with stopper made with butyl rubber polymer coated with a fluorocarbon polymer resin.

#### Solvent:

Type I glass vial of 1 ml of solvent closed with butyl elastomer rubber stopper.

#### For the 5 MU presentation:

Cardboard box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent

#### For the 10 MU presentation:

Cardboard box containing 1 vial of lyophilisate and 1 vial with 1 ml of solvent

Cardboard box containing 2 vials of lyophilisate and 2 vials with 1 ml of solvent

Cardboard box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

## **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/01/030/001

EU/2/01/030/002

EU/2/01/030/003

EU/2/01/030/004

## **8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 06/11/2001

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

<{DD/MM/YYYY}>

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None.



**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Virbagen Omega 5 MU lyophilisate and solvent for suspension for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 1 ml contains:

Lyophilisate:

Recombinant Omega interferon of feline origin                      5 MU\*

\*MU : Million Units

**3. PACKAGE SIZE**

Box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent.

**4. TARGET SPECIES**

Dogs and cats.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Dogs: Intravenous use

Cats: Subcutaneous use

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated (2 °C – 8°C).

Do not freeze.

Store in the original package.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/01/030/001

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Virbagen Omega 10 MU lyophilisate and solvent for suspension for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 1 ml contains:

Lyophilisate:

Recombinant Omega interferon of feline origin            10 MU\*

\*MU : Million Units

**3. PACKAGE SIZE**

Box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent.

**4. TARGET SPECIES**

Dogs and cats.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Dogs: Intravenous use

Cats: Subcutaneous use

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated (2°C – 8°C).

Do not freeze.

Store in the original package.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/01/030/002

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Box containing 2 vials of lyophilisate and 2 vials with 1 ml of solvent**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Virbagen Omega 10 MU lyophilisate and solvent for suspension for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 1 ml contains:

Lyophilisate:

Recombinant Omega interferon of feline origin                      10 MU\*

\*MU : Million Units

**3. PACKAGE SIZE**

Box containing 2 vials of lyophilisate and 2 vials with 1 ml of solvent.

**4. TARGET SPECIES**

Dogs and cats.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Dogs: Intravenous use

Cats: Subcutaneous use

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated (2°C – 8°C).

Do not freeze.

Store in the original package.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/01/030/003

**15. BATCH NUMBER**

Lot {number}



**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Box containing 1 vial of lyophilisate and 1 vial with 1 ml of solvent**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Virbagen Omega 10 MU lyophilisate and solvent for suspension for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 1 ml contains:

Lyophilisate:

Recombinant Omega interferon of feline origin                      10 MU\*

\*MU : Million Units

**3. PACKAGE SIZE**

Box containing 1 vial of lyophilisate and 1 vial with 1 ml of solvent.

**4. TARGET SPECIES**

Dogs and cats.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Dogs: Intravenous use

Cats: Subcutaneous use

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated (2°C – 8°C).

Do not freeze.

Store in the original package.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/01/030/004

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**LYOPHILISATE VIAL**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Virbagen Omega



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

5 MU

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**LYOPHILISATE VIAL**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Virbagen Omega



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

10 MU

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**  
**SOLVENT VIAL**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Virbagen Omega solvent



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

1 ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Virbagen Omega 5 MU lyophilisate and solvent for suspension for injection for dogs and cats  
Virbagen Omega 10 MU lyophilisate and solvent for suspension for injection for dogs and cats

### 2. Composition

Each dose of 1 ml contains:

#### Active substance:

Lyophilisate:

5 MU presentation:

Recombinant Omega interferon of feline origin 5 MU\*

10 MU presentation:

Recombinant Omega interferon of feline origin 10 MU\*

\*MU : Million Units

Lyophilisate: white colour

Solvent: colourless liquid

### 3. Target species

Dogs and cats.

### 4. Indications for use

#### Dogs:

Reduction of mortality and clinical signs of parvovirus (enteric form) in dogs from one month of age.

#### Cats:

Treatment of cats infected with FeLV and/or FIV, in non-terminal clinical stages, from the age of 9 weeks. In a field study conducted, it was observed that there was:

- a reduction of clinical signs during the symptomatic phase (4 months)

- a reduction of mortality :

- in anaemic cats, mortality rate of about 60 % at 4, 6, 9 and 12 months was reduced by approximately 30 % following treatment with interferon.
- in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20 % following treatment with interferon. In cats infected by FIV, mortality was low (5 %) and was not influenced by the treatment.

### 5. Contraindications

Dogs: Vaccination during and after Virbagen Omega treatment is contra-indicated, until the dog appears to have recovered.

Cats: as vaccination is contra-indicated in the symptomatic phase of FeLV/FIV infections, the effect of Virbagen Omega on cat vaccination has not been evaluated.

## **6. Special warnings**

### Special warnings:

No information on the induction of long-term side effects is available in dog and cat, especially for autoimmune disorders. Such side effects have been described after multiple and long-term administration of type I interferon in man. The possibility of occurrence of autoimmune disorders in treated animals cannot therefore be ruled out and has to be balanced with the risk associated with FeLV/FIV infections.

Efficacy of the product on cats with a tumorous form of the infection by FeLV, or cats infected by FeLV or coinfecting by FIV in terminal stages was not tested.

In the case of intravenous administration in cats, increased adverse reactions may be seen, e.g. hyperthermia, soft faeces, anorexia, decreased drinking or collapse.

### Special precautions for safe use in the target species:

Dogs and cats: it was shown that strict compliance with the recommended posology is compulsory to achieve clinical benefit.

Cats: In case of repeated treatments of chronic diseases associated with hepatic, cardiac and renal failure, the corresponding disease has to be monitored prior to administration of Virbagen Omega.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

### Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

### Interaction with other medicinal products and other forms of interaction:

The use of supplementary supportive treatments improves prognosis. No interaction has been observed during the treatment with Virbagen Omega together with antibiotics, solution for rehydration, vitamins and non steroidal anti-inflammatory agents. However, as specific information on possible interactions of interferon with other products are missing, supplementary supportive treatments should be used cautiously and after a thorough risk/benefit analysis.

No information is available on the safety and efficacy when used with any other vaccine. For dogs, it is recommended that no vaccines should be administered until the animal appears to have recovered. Cat vaccination during and after Virbagen Omega treatment is contra-indicated as both FeLV and FIV infections are known to be immunosuppressive.

### Overdose:

After a tenfold overdose in both dog and cat the following clinical signs have been observed:

- mild lethargy and drowsiness
- slight increase of body temperature.
- slight increase of respiratory rate



- slight sinus tachycardia.

These clinical signs disappear within 7 days without any particular treatment.

Major incompatibilities:

Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the product.

**7. Adverse events**

Dogs:

Very common (>1 animal / 10 animals treated):
Decreased white blood cells <sup>1</sup> , Decreased platelet count <sup>1</sup> , Decreased red blood cell count <sup>1</sup> , Elevated alanine aminotransferase (ALT) <sup>1</sup>
Common (1 to 10 animals / 100 animals treated):
Hyperthermia <sup>2,3</sup> Lethargy <sup>2</sup>

<sup>1</sup>Slight, Return to normal in the week following the last injection.

<sup>2</sup>Slight and Transient.

<sup>3</sup>3-6 hours after injection.

Cats:

Very common (>1 animal / 10 animals treated):
Decreased white blood cells <sup>1</sup> , Decreased platelet count <sup>1</sup> , Decreased red blood cell count <sup>1</sup> , Elevated alanine aminotransferase (ALT) <sup>1</sup>
Common (1 to 10 animals / 100 animals treated):
Hyperthermia <sup>2,3</sup> Lethargy <sup>2</sup> Digestive tract disorders (e.g. Diarrhoea, Vomiting) <sup>2</sup>

<sup>1</sup>Slight, Return to normal in the week following the last injection.

<sup>2</sup>Slight and Transient.

<sup>3</sup>3-6 hours after injection.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

**8. Dosage for each species, routes and method of administration**

Dogs: The dose is 2.5 MU/kg bodyweight.

Cats: The dose is 1 MU/kg bodyweight.

The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain, depending on the presentation, a limpid and colourless suspension containing 5 MU or 10 MU of recombinant interferon.

Dogs: The reconstituted product should be injected intravenously once daily for 3 consecutive days.

Cats: The reconstituted product should be injected subcutaneously once daily for 5 consecutive days.

Three separate 5-day treatments must be performed at day 0, day 14 and day 60.

The product should be used immediately after reconstitution.

#### **9. Advice on correct administration**

The freeze-dried fraction must be reconstituted with 1 ml of the specific diluent to obtain, depending on the presentation, a limpid and colourless suspension.

Dogs and cats: it was shown that strict compliance with the recommended posology is compulsory to achieve clinical benefit.

Cats: In case of repeated treatments of chronic diseases associated with hepatic, cardiac and renal failure, the corresponding disease has to be monitored prior to administration of Virbagen Omega. The use of supplementary supportive treatments improves prognosis. The veterinary medicinal product should be used with the accompanying solvent only.

#### **10. Withdrawal periods**

Not applicable.

#### **11. Special storage precautions**

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Store in the original carton.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the vial label after Exp. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: use immediately.

#### **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

#### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

#### **14. Marketing authorisation numbers and pack sizes**

EU/2/01/030/001

EU/2/01/030/002

EU/2/01/030/003

EU/2/01/030/004

For the 5 MU presentation:

Cardboard box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent

For the 10 MU presentation:

Cardboard box containing 1 vial of lyophilisate and 1 vial with 1 ml of solvent

Cardboard box containing 2 vials of lyophilisate and 2 vials with 1 ml of solvent

Cardboard box containing 5 vials of lyophilisate and 5 vials with 1 ml of solvent

Not all pack sizes may be marketed.

## **15. Date on which the package leaflet was last revised**

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

## **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release:

VIRBAC  
1<sup>ère</sup> Avenue 2065m LID  
06516 CARROS  
France

Local representatives and contact details to report suspected adverse reactions:

### **Österreich**

VIRBAC Österreich GmbH  
Hildebrandgasse 27  
A-1180 Wien  
Tel: + 43-(0) 1 21 834 260

### **België/Belgique/Belgien**

VIRBAC Belgium NV  
Esperantolaan 4  
BE-3001 Leuven  
België / Belgique / Belgien  
Tél/Tel: +32-(0)16 387 260  
phv@virbac.be

### **Република България**

ЕРГОН МИЛАНОВА ЕООД  
с. Бърложница 2222, Софийска област  
Република България  
Тел: + 359 888215520  
ergonood@gmail.com

### **Κύπρος**

VET2VETSUPPLIES LTD  
Γαλιλαίου 60  
3011 Λεμεσος  
Κύπρος  
Τηλ: + 357 96116730  
info@vet2vetsupplies.com

### **Česká republika**

VIRBAC Czech Republic s.r.o.  
Žitavského 496  
156 00 Praha 5  
Česká republika  
Tel.: +420 608 836 529

### **Deutschland**

VIRBAC Tierarzneimittel GmbH  
Rögen 20  
23843 Bad Oldesloe  
Deutschland  
Tel: + 49 (4531) 805 111

### **Danmark**

VIRBAC Danmark A/S  
Profilverj 1  
6000 Kolding

### **Eesti**

OÜ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa

**Danmark**  
Tel: +45 75521244  
virbac@virbac.dk

**España**  
VIRBAC ESPAÑA S.A.  
Angel Guimera 179-181  
ES-08950 - Esplugues de Llobregat  
(Barcelona)  
Tel: + 34 93 470 79 40

**France**  
VIRBAC France  
13<sup>ème</sup> rue LID  
FR-06516 Carros  
service-conso@virbac.fr

**Hrvatska**  
CENTRALNA VETERINARSKA AGENCIJA  
d.o.o. (CVA)  
Prve Ravnice 2e, 10000 Zagreb  
Republika Hrvatska  
Tel.: + 385 91 46 55 115  
kz@cva.hr

**Ireland**  
VIRBAC IRELAND  
McInerney & Saunders  
38, Main Street  
Swords, Co Dublin  
K67E0A2  
Republic Of Ireland  
Tel: +44 (0)-1359 243243

**Italia**  
VIRBAC SRL  
Via Ettore Bugatti 15  
IT-20142 Milano  
Tel: + 39 02 40 92 47 1

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Belgique / Belgien  
Tél/Tel: +32-(0)16 387 260  
info@virbac.be

**Eesti**  
Tel: + 372 56480207  
pv@zoovet.eu

**Suomi/Finland**  
VIRBAC  
1<sup>ère</sup> avenue 2065m LID  
FR-06516 Carros Ranska  
Puh/Tel: + 33 (0) 4 92 08 73 00

**Ελλάδα**  
VIRBAC ΕΛΛΑΣ ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ: +30 2106219520  
info@virbac.gr

**Magyarország**  
VIRBAC HUNGARY KFT  
Váci utca 81. 4 emelet.  
HU-1056 Budapest  
Tel.: +36703387177  
akos.csoman@virbac.hu

**Ísland**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – L.I.D  
FR-06516 Carros Frakkland  
Simi: + 33 (0) 4 92 08 73 00

**Lietuva**  
OÜ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa  
Estija  
Tel: + 372 56480207  
pv@zoovet.eu

**Latvija**  
OÜ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa  
Igaunija  
Tel: + 372 56480207  
pv@zoovet.eu

**Malta**

VIRBAC  
1<sup>re</sup> avenue 2065m LID  
FR-06516 Carros Franza  
Tel: + 33 (0) 4 92 08 73 00

**Norge**

VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Danmark  
Tel: + 45 75521244  
virbac@virbac.dk

**Portugal**

VIRBAC de Portugal Laboratórios, Lda.  
Rua do Centro Empresarial  
Edif.13 - Piso 1- Escrit.3  
Quinta da Beloura  
PT-2710-693 Sintra (Portugal)  
Tel: + 351 219 245 020

**Slovenija**

MEDICAL INTERTRADE d.o.o.  
Brodišče 12, 1236 Trzin  
Slovenija  
Tel: + 386 1 2529 113  
farmakovigilanca@medical-intertrade.si

**SE: Sverige**

VIRBAC Danmark A/S Filial Sverige  
Box 1027  
SE-171 21 Solna  
Tel: +45 75521244  
virbac@virbac.dk

**Nederland**

VIRBAC NEDERLAND BV  
Hermesweg 15  
3771 ND-Barneveld  
Tel: + 31 (0) 342 427 127  
phv@virbac.nl

**Polska**

VIRBAC Sp. z o.o.  
ul. Puławska 314  
PL 02-819 Warszawa  
Tel.: + 48 22 855 40 46

**România**

Altius SA  
Str. Zăgazului nr. 21-25, Corp A, et 8 si 8A  
Ap. A.8.2, sect 1, București,  
Romania  
Tel: + 40 021 310 88 80

**Slovenská republika**

VIRBAC Czech Republic s.r.o.  
Žitavského 496  
156 00 Praha 5  
Česká republika  
Tel.: +420 608 836 529

**UK: United Kingdom (Northern Ireland)**

VIRBAC IRELAND  
McInerney & Saunders  
38, Main Street  
Swords, Co Dublin  
K67E0A2  
Republic Of Ireland  
Tel: +44 (0)-1359 243243

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.